7月31日，科伦博泰生物盘中上涨3.78%，报499.0港元/股，成交额5879.98万港元。
消息面上，公司于7月30日公告，核心产品芦康沙妥珠单抗用于PD-L1综合阳性评分＜10或早期接受过PD-1/PD-L1抑制剂的复发或转移性三阴性乳腺癌一线治疗的新增适应症上市申请已获NMPA受理，并纳入优先审评审批程序。这是芦康沙妥珠单抗第六项获受理的适应症上市申请，该产品已在中国获批4项适应症。此外，合作方默沙东近期启动了芦康沙妥珠单抗联合PD-1/VEGF双抗的II期临床研究，进一步拓展联合用药布局。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.